JPH05501857A - 感光性ディールス―アルダーポルフィリン誘導体 - Google Patents

感光性ディールス―アルダーポルフィリン誘導体

Info

Publication number
JPH05501857A
JPH05501857A JP2508586A JP50858690A JPH05501857A JP H05501857 A JPH05501857 A JP H05501857A JP 2508586 A JP2508586 A JP 2508586A JP 50858690 A JP50858690 A JP 50858690A JP H05501857 A JPH05501857 A JP H05501857A
Authority
JP
Japan
Prior art keywords
aryl
alkyl
target
formula
light
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2508586A
Other languages
English (en)
Japanese (ja)
Inventor
ドルフィン,デイビッド
ヒン,ポール ヨン
ウィジェセケラ,ティラック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Publication of JPH05501857A publication Critical patent/JPH05501857A/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2508586A 1989-06-07 1990-06-07 感光性ディールス―アルダーポルフィリン誘導体 Pending JPH05501857A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36318589A 1989-06-07 1989-06-07
US363,185 1989-06-07

Publications (1)

Publication Number Publication Date
JPH05501857A true JPH05501857A (ja) 1993-04-08

Family

ID=23429184

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2508586A Pending JPH05501857A (ja) 1989-06-07 1990-06-07 感光性ディールス―アルダーポルフィリン誘導体

Country Status (5)

Country Link
EP (1) EP0476011A1 (fr)
JP (1) JPH05501857A (fr)
AU (1) AU641658B2 (fr)
CA (1) CA2056431A1 (fr)
WO (1) WO1990015059A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000514034A (ja) * 1995-04-13 2000-10-24 ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ 作用物質、ポリエーテル及び任意に身体に許容可能とみなされる天然性蛋白質からなるコンジュゲート

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9014307D0 (en) * 1990-06-27 1990-08-15 Scient Generics Ltd Method of treatment and compositions therefor
EP0649667B1 (fr) * 1993-10-20 2001-02-28 Antonella Aprile Carpenter Appareil thérapeutique de stimulation biologique à niveau d'énergie quantique
US6444194B1 (en) * 1997-02-14 2002-09-03 Miravant Pharmaceuticals, Inc. Indium photosensitizers for PDT
US6756396B1 (en) 1997-05-07 2004-06-29 Qlt Inc. Ethylene glycol esters as photoactive agents
CZ294715B6 (cs) * 1997-05-07 2005-02-16 Qlt Inc. Ethylenglykol estery monohydrobenzoporfyrinových derivátů jako fotoaktivní činidla
US10919904B2 (en) 2016-08-17 2021-02-16 North Carolina State University Northern-southern route to synthesis of bacteriochlorins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986001720A1 (fr) * 1984-09-13 1986-03-27 Cytogen Corporation Conjugues d'agents therapeutiques-anticorps
US4920143A (en) * 1987-04-23 1990-04-24 University Of British Columbia Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents
US4883790A (en) * 1987-01-20 1989-11-28 University Of British Columbia Wavelength-specific cytotoxic agents
EP0434727A4 (en) * 1988-09-08 1994-08-17 Ultra Diagnostic Corp Red-shifted phthalocyanine and tetrabenztriazaporphyrin reagents

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000514034A (ja) * 1995-04-13 2000-10-24 ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ 作用物質、ポリエーテル及び任意に身体に許容可能とみなされる天然性蛋白質からなるコンジュゲート

Also Published As

Publication number Publication date
AU5816490A (en) 1991-01-07
AU641658B2 (en) 1993-09-30
CA2056431A1 (fr) 1990-12-08
EP0476011A1 (fr) 1992-03-25
WO1990015059A1 (fr) 1990-12-13

Similar Documents

Publication Publication Date Title
US5095030A (en) Wavelength-specific cytotoxic agents
CA1339927C (fr) Agents cytotoxiques specifiques pour les longeurs d'onde
CA1333442C (fr) Agents cytotoxiques specifiques de longueur d'ondes
US5004811A (en) Tetrapyrrole aminocarboxylic acids
US4968715A (en) Use of purified hematoporphyrin trimers in photodynamic therapy
US5308608A (en) Photosensitizing Diels-Alder porphyrin derivatives
US5190966A (en) Purified hematoporphyrin dimers and trimers useful in photodynamic therapy
JP3108438B2 (ja) 波長特異的感光性ポルファシアニン、拡大されたポルフィリン様化合物及び調製のための方法とその使用
US5238940A (en) Compositions for photodynamic therapy
US5149708A (en) Photosensitizing Diels-Alder porphyrin derivatives
US5268371A (en) Derivatives of porphyrin and metalloporphyrins optionally coupled to a biologically active molecule and pharmaceutical composition containing them
Karges et al. Synthesis and Characterization of an Epidermal Growth Factor Receptor‐Selective RuII Polypyridyl–Nanobody Conjugate as a Photosensitizer for Photodynamic Therapy
JF Calvete et al. Tetrapyrrolic macrocycles: Potentialities in medical imaging technologies
JPH0794392B2 (ja) 新規なテトラピロ−ルポリアミノモノカルボン酸医薬用組成物
WO1991014456A2 (fr) Compositions de therapie photodynamique ameliorees
JPS6183186A (ja) 新規なテトラピロ−ル医薬用組成物
KR100358273B1 (ko) 광감작제
Srivatsan et al. In vitro cellular uptake and dimerization of signal transducer and activator of transcription-3 (STAT3) identify the photosensitizing and imaging-potential of isomeric photosensitizers derived from chlorophyll-a and bacteriochlorophyll-a
JPH05501857A (ja) 感光性ディールス―アルダーポルフィリン誘導体
JP2020512329A (ja) 生体適合性モジュール式テトラジンプラットフォーム
WO2020084267A1 (fr) Nouveaux composés et leurs utilisations pour l'imagerie par la luminescence cherenkov proche infrarouge et/ou pour le traitement des tissus profonds par photothérapie dynamique cherenkov
Kuzmina et al. The Development of meso-Methyl-BODIPY Conjugates with Boc-seco-CBI and Cabozantinib: The Practical Challenges of Red-Light-Activated Prodrugs for Anticancer PDT
JP2008512404A (ja) ホウ素化された金属フタロシアニン、その調製方法、これを有する医薬組成物及びその使用
NO179410B (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive monobenzofyriner og anvendelse av disse
JPH02149519A (ja) 波長特異的細胞毒性試薬